In
1965, Schildkraut postulated that noradrenaline may play a pivotal role in the aetiology of depression. In favour of
this hypothesis was the observation that the antihypertensive
drug reserpine, which depletes central and peripheral vesicular
stores of catecholamines such as noradrenaline, can precipitate
depression in patients in remission.
The experimental drug
-methyl-paratyrosine that blocks the synthesis of noradrenaline and dopamine by inhibiting the rate-limiting enzyme tyrosine hydroxylase also precipitates depression in patients during remission. Such findings are only
indirect indicators that noradrenaline plays an important role
in human behaviour, and may be defective in depression –
more direct evidence is needed to substantiate the hypothesis.
In depression, it should be emphasised that the reduced growth
hormone response to clonidine cannot be accounted for by the
drug treatment, age or gender of the patient, which supports
the view that the noradrenergic system is dysregulated. Lastly,
determination of the urine or plasma concentrations of MHPG
(an indicator of central noradrenergic activity), suggests that
central noradrenergic function is sub-optimal in depression.
Taken together, these results suggest that central noradrenergic
function is decreased in depression, an event leading to an
increase in the density of the post-synaptic ß-adrenoceptors
(
Leonard, 1986;
Dinan, 1994).
The role of serotonin (5-hydroxytryptamine, 5-HT) has also been
extensively studied in patients with depression. Whereas the
overall psychophysiological effects of noradrenaline in the
central nervous system appear to be linked to drive and motivation,
5-HT is primarily involved in the expression of mood (see
Charney et al, 1991).
The main 5-HT metabolite, 5-hydroxyindole acetic
acid (5-HIAA), is reduced in the cerebrospinal fluid (CSF) of
patients with severe depression, as are 5-HT and 5-HIAA in the
limbic regions of the brain of suicide victims (
Agren, 1980).
Serotonin receptor function is also abnormal in depression with
an increase in the density of cortical 5-HT
2a receptors in the
brains of suicide victims and also on the platelet membrane
of patients with depression.
Dopaminergic function Studies on platelets, lymphocytes, changes in cerebrospinal
fluid metabolites of brain monoamines and post-mortem studies
suggest that a major abnormality in both noradrenergic and serotonergic
function occurs in depression, and that such changes could be
causally related to the disease process.
Less attention has been paid to the possible involvement of
dopamine in this disorder. However, anhedonia is a characteristic
feature of major depression, and a defect in dopaminergic function
is thought to be causally involved in this symptom (
Willner, 1983).
The concentration of the main dopamine metabolite, homovanillic
acid (HVA), is decreased in the CSF of patients with depression,
particularly those with psychomotor retardation.
Advances in Psychiatric Treatment (2000) 6: 178-186
© 2000 The Royal College of Psychiatrists
Clinical implications of mechanisms of action of antidepressants
Brian Leonard